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Implantable cardioverter-
defibrillators in congenital heart
disease
Introduction
Sudden cardiac death (SCD) is a ma-
jor cause of mortality in the congeni-
tal heart disease (CHD) population [40].
A large proportion of these deaths are
caused by ventricular arrhythmias that
may be amenable to timely cardiover-
sion by implantable cardioverter-deﬁb-
rillators (ICD); however, the selection of
patients, mode of implantation and long-
term management of the devices in the
CHDpopulation is challenging. In sucha
heterogeneous patient group, robust ev-
idence-based guidelines are ﬂexible by
deﬁnition. This review discusses these
concerns in the light of recent publica-
tions.
Indications
The CHD population represents a very
small minority of ICD implantations but
has been relatively well-deﬁned in reg-
istries and thorough meta-analyses [1,
13, 39]. There is a surprisingly wide
Fig. 19Distribution
of congenital heart dis-
ease (CHD) implantable
cardioverter-deﬁbrillator
population by CHD lesion.
Figures are adapted from
the two largest population
studies. The 1304 patients
reported by Jordan et al
with atrial septal defect
(ASD) alone are excluded.
Nopatients with VSD alone
were reportedby Berul et al
[3, 13]
variance in composition of CHD ICD
cohorts, which is likely to reﬂect both
coding as well as clinical practice ([3, 13,
25], . Fig. 1).
Consensus guidelines for arrhythmia
management in adult CHD[18] and pae-
diatric [4] populations have been pub-
lished, establishing the broad indications
for ICD implantation in theCHDcohorts
and these should be interpreted in the
context of the 2008 American Heart As-
sociation (AHA) device guidelines and
the 2015 European Society of Cardiology
(ESC) guidelines on the management of
ventricular arrhythmias [10, 42].
Secondary prevention
Therole of ICD implantation inCHDpa-
tients following resuscitation for cardiac
arrest is usually self-evident and in the
absence of a clearly reversible cause this
is a class 1 (level B) indication (. Tab. 1).
The implantation of ICD is also recom-
mended for symptomatic and sustained
ventricular tachycardia (VT), in the ab-
sence of loss of cardiac output, following
detailed evaluation (class 1, level B).
In a small subgroup of patients with
sustained VT, the option of catheter ab-
lation alone is tantalising. Small studies
have demonstrated high rates of long-
term VT-free survival in patients for
whom a critical isthmus is transected via
catheter ablation [28, 43], particularly
in those who remain recurrence-free
after the ﬁrst 2 months postablation.
There may be a place in a highly selected
patient group for management without
ICD implantation [10], possibly with
short-term management with a wearable
deﬁbrillator but amore detailed evidence
base is required to engender conﬁdence
in such an approach.
Primary prevention
Approximately half of all ICD implanta-
tions in CHD are for primary prevention
[3, 13, 25, 39] and the indications for this
cohort remain uncertain. The overall ap-
propriate shock rate is highly dependent
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Tab. 1 Recommendations formanagement of ventricular arrhythmias in patientswith congen-
ital heart disease.Adapted from the 2015 European Society of Cardiology guidelines for theman-
agement of patients with ventricular arrhythmias (Priori et al.) [42]
Class Clinical indication Level of
evidence
Class I After evaluation to deﬁne the cause of the event and exclude any
reversible causes, ICD implantation is recommended for patients with
CHD who are survivors of an aborted cardiac arrest
B
ICD implantation is recommended for patients with CHD with symp-
tomatic sustained VT who have undergone haemodynamic and elec-
trophysiological evaluation
B
Catheter ablation is recommended as additional therapy or an alter-
native to ICD in patients with CHD who have recurrent monomorphic
VT or appropriate ICD therapies that are not manageable by device
reprogramming or drug therapy
C
ICD therapy is recommended in adults with CHD and a systemic LVEF
< 35%, biventricular physiology, symptomatic HF despite optimal
medical treatment and NYHA functional class II or III
C
Class IIa ICD implantation should be considered in patients with CHD with
syncope of unknown origin in the presence of either advanced ven-
tricular dysfunction or inducible sustained VT or VF on PVS
B
ICD implantation should be considered in selected patients with
tetralogy of Fallot and multiple risk factors for SCD, including LV
dysfunction, non-sustained VT, QRS duration > 180 ms or inducible
sustained VT on PVS
B
Catheter ablation should be considered as an alternative to drug
therapy for symptomatic sustainedmonomorphic VT in patients with
CHD and an ICD
B
Class IIb ICD therapymay be considered in patients with advanced single or
systemic RV dysfunction in the presence of other risk factors such as
non-sustained VT, NYHA functional class II or III or severe systemic AV
valve regurgitation
B
PVSmay be considered for risk stratiﬁcationof SCD in patients with
tetralogy of Fallot who have one or more risk factors among LV dys-
function, non-sustained VT and QRS duration > 180 ms
B
PVSmay be considered in patients with CHD and non-sustained VT to
determine the risk of sustained VT
C
Surgical ablation guided by electrophysiologicalmappingmay be
considered in patients with CHD undergoing cardiac surgery, with
clinical sustained VT and with inducible sustainedmonomorphic VT
with an identiﬁed critical isthmus.
C
Class III PVS is not recommended to stratify the risk in patients with CHD in
the absence of other risk factors or symptoms
C
AV atrioventricular,CHD congenital heart disease,HFheart failure, ICD implantable cardioverter-de-
fibrillator, LV left ventricle, LVEF left ventricular ejection fraction, NYHA New York Heart Association,
PVS programmed ventricular stimulation, RV right ventricle, VF ventricular fibrillation, VT ventricular
tachycardia
on the indications but occurs in approx-
imately 1 in 5 patients over the ﬁrst 3
years postimplantation [39], a surpris-
ingly high proportion compared to the
non-CHD population; however, this ﬁg-
ure needs to be weighed up against the
relatively high ICD-related complication
rate of 1 in 4 and the additional inappro-
priate shock rate of 1 in 4, both over 3
years [1, 39, 41]. Furthermore, appropri-
ate shocks do not always indicate aborted
death and the balance of risk and beneﬁt
therefore requires careful evaluation.
The indications for primary preven-
tion are most frequently non-sustained
VT, impaired systemic ventricular func-
tionand syncope. Symptomatic non-sus-
tainedVTand subpulmonaryventricular
dysfunction have been shown to be asso-
ciated with appropriate shocks [25]. The
role of programmed ventricular stimula-
tion (PVS) studies remains controversial
with conﬂicting evidence, but this may
reﬂecttosomedegreethediﬀerentpatient
substrate. Surprisingly and importantly,
ameta-analysis showed that the presence
of inducible VT does not predict appro-
priate interventions (odds ratio1.2, range
0.2–5.7) [39].
Tetralogy of Fallot
The most detailed data for primary pre-
vention ICD inCHDrelates to thosewith
repaired tetralogy of Fallot (ToF). For
these patients, the risk of SCD is approx-
imately2–3%perdecade[42]andanum-
ber of risk factors have been identiﬁed
that delineate increased risk and there-
fore the group that will derive greatest
beneﬁt fromICDimplantation (. Tab. 2).
Raised leftventricular end-diastolic pres-
sure (LVEDP), pulmonary artery pres-
sure and right ventricular (RV) systolic
pressure are the strongest predictors of
appropriate shock therapy. The signiﬁ-
canceof inducible sustainedVTonPVS is
unclear, with a trend towards increased
incidence of appropriate shocks in in-
ducible patients [20, 24]. Retrospective
studies have reported appropriate shock
rates ashighas 17%per year forhigh-risk
primary prevention (risk score 6–12) but
with an inappropriate shock rate of 5.8 %
per year and other system complications
occurring in nearly 30% [20].
Failing systemic ventricle
The use of ICD should be considered
in patients who meet the established
class I indications for the failing left
ventricle, including LV ejection fraction
< 35% with New York Heart Association
(NYHA) class II or III symptoms ([10,
42], . Tab. 1); however, only a very small
proportion of patients with CHD will
meet these criteria and the indications
for ICD implantation in the context
of systemic ventricular dysfunction are
much more nuanced.
Proponents [36] and antagonists [38]
have made well-reasoned arguments for
and against the routine role of ICD in the
failing systemic ventricle, particularly as
the ejection fraction fallsbelow30 %. The
applicability of the major non-CHD ICD
trial data to a CHDcohort is highly ques-
tionable, with very diﬀerent pathophys-
iology and risk-beneﬁt proﬁles. There
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are certainly selected patient groups that
stand to have lives saved through ap-
propriate therapies. The identiﬁcation,
though, of these patients requires fur-
ther investigation.
Atrial switch
In patientswith transpositionof the great
arteries (TGA) treated by an atrial switch
procedure (Mustard or Senning), the risk
of SCD is approximately 5% per decade
of life and atrial arrhythmias appear to
be a strong predictor of events [15]; how-
ever, appropriate shock rates for primary
prevention ICDs are lower in this patient
group than ToF, at approximately 0.5 %
per year and the indications should be
carefully considered [16].
Risk factors for appropriate therapies
are thought to include wide QRS du-
ration, systemic atrioventricular (AV)
valve regurgitation and systemic right
ventricular (RV) dysfunction. Systemic
RV function cut-oﬀ values have been
diﬃcult to deﬁne but are likely to be
lower than the 35% for LV dysfunction
and should be weighed up against rel-
atively high complication rates (14 out
of 37 TGA patients [38 %] in the largest
cohort study [19]). PVS does not appear
to be a useful predictor of events.
Univentricular heart
Patients with univentricular circulation
diﬀer widely in terms of underlying car-
diac morphology and subsequent surgi-
cal strategy and data on the eﬃcacy of
ICD therapy is scarce. Atrial arrhythmias
are commonbut there is also a signiﬁcant
incidence of arrhythmia-related SCD, re-
ported to be up to 10% over 10 years
[17]. Most ICD in this patient group are
implanted for secondary prevention or
in the context of severe univentricular
systolic dysfunction. Formal risk factor
stratiﬁcation is lacking and the role of
PVS is unknown.
Implantation
Transvenous ICD systems make up the
vast majority of implantations in the
largest registries (typically 97% of the
paediatric and CHD population [13]).
Transvenous implantation is generally
felt to be preferable to non-transvenous
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have an important role in reducing sudden
cardiac death in patients with congenital
heart disease (CHD); however, the beneﬁt
of ICDs needs to be weighed up against
both short-term and long-term adverse
eﬀects, which are diﬃcult to evaluate in
the heterogeneous CHD population. A
tailored approach, taking into account risk
stratiﬁcation and patient-speciﬁc factors,
is needed to select the most appropriate
strategy. This review discusses primary and
secondary ICD indications, implantation
approaches and long-term follow-up. Recent
publications have shed light on the concerns
of system longevity, lead extractions,
inappropriate shocks and impact on the
quality of life. All of these factors require




Congenital heart disease · Ventricular
tachycardia · Sudden cardiac death




(ICD) spielen bei Patientenmit angeborenen
Herzfehlern (AHF) eine entscheidende Rolle
bezüglich der Reduktion des plötzlichen
Herztods. Die Vorteile einer ICD-Implantation
müssen jedoch den potenziellen akuten,
aber auch langfristigen Komplikationen
gegenübergestellt werden, was insbesondere
bei der Gruppe der AHF-Patienten schwierig
ist. Individuelle Strategien, die den patienten-
speziﬁschen Faktoren einerseits und der
notwendigen Risikostratiﬁzierung anderer-
seits Rechnung tragen, müssen sorgfältig
erarbeitet werden. In diesemÜbersichtsartikel
werden die ICD-Indikationen zur Primär- und
Sekundärprophylaxe, die Implantationstech-
niken und die Ergebnisse aus der langfristigen
Nachbeobachtung diskutiert. Daten aus
aktuellen Studien belegen speziﬁsche Limi-
tationen bezüglich Haltbarkeit der Systeme,
Umsetzbarkeit von Sondenextraktionen,
inadäquaten Schockabgaben und Reduktion
der Lebensqualität. Alle diese Faktoren
müssen sorgsam abgewogen werden, bevor
bei Patientenmit angeborenen Herzfehlern
über eine ICD-Implantation als langfristige
Behandlungsstrategie entschiedenwird.
Schlüsselwörter
ICD · Angeborene Herzfehler · Ventrikuläre
Tachykardie · Plötzlicher Herztod
on account of superior system longevity
(system survival at 3 years 76% versus
49%, respectively [34]) anddeﬁbrillation
eﬃcacy (failure to cardiovert 0.2 % ver-
sus 3.7 %, respectively [13]). However,
these advantages need to be weighed
up against the requirement for lead(s)
in the vascular system, subsequent lead
extraction and high risk baﬄe punc-
tures; therefore, in selected cases a non-
transvenous system remains the most
suitable option. A detailed understand-
ing of cardiac anatomy and prior surgical
and interventional procedures is manda-
tory, and frequently up to date imaging,
including computed tomography (CT),
magnetic resonance imaging (MRI) and
venography are necessary to clarify the
substrate before implantation. Place-
ment of a lead into a systemic ventricle
or in the presence of a right to left shunt
is possible but subsequent long-term
anticoagulation is indicated [4, 21].
Transvenous systems
In adult practice, ICDs can be inserted in
a subcutaneous or submuscular pocket
with the patient under local anaes-
thesia with sedation, with all leads
implanted transvenously. For children
above 20–25 kg in weight, small ICDs
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Tab. 2 Predictors of appropriate implantable cardioverter-deﬁbrillator therapy in primary pre-
ventative therapyof tetralogyofFallot (0–2points is lowrisk,3–5points intermediate riskand6–12
points high risk. Adapted fromKhairy et al. [20]). Signiﬁcant factors onunivariate andmultivariate
analysis are highlighted in italics






Prior palliative shunt 2.6 0.7–9.4 0.13 2
Inducible sustained VT 2.1 0.6–7.6 0.24 2
QRS duration, per 1 ms 1.01 0.99–1.03 0.21
QRS ≥ 180 ms 2.0 0.7–5.9 0.22 1
Ventriculotomy incision 2.4 0.9–6.1 0.071 2
Nonsustained VT 2.7 1.0–7.2 0.053 0.023 2
RV systolic pressure, per
1 mmHg
1.06 1.01–1.11 0.0301
Mean PAP, per 1 mmHg 1.16 1.05–1.35 0.0032
LVEDP, per 1 mmHg 1.21 1.08–1.35 0.0008 0.0039
LVEDP ≥ 12mmHg 15.1 1.9–123.7 0.0114 0.022 3
HR hazard ratio, CI confidence interval, VT ventricular tachycardia, PAP pulmonary artery pressure,
LVEDP left ventricular end diastolic pressure, RV right ventricle
can be implanted in a similar fashion
under general anaesthesia but for those
weighing 10– 20 kg an abdominal pocket
for the generator should be considered,
with leads tunnelled to the subclavian
vein (. Fig. 2a, b). Below 10 kg, a non-
transvenous system should generally be
considered ([4], . Fig. 2c, d).
Modern lead sizes are only marginally
larger than pacemaker leads but histor-
ically results for thin leads (≤ 7Fr) have
been confounded by issues with lead
failures and recalls for Sprint Fedelis
(Medtronic, Minneapolis, MN) and Ri-
ata (St Jude, Little Canada, MN) leads.
Smaller contemporary leads include the
Durata (St Jude, 7Fr) and the Protego
(Biotronik, Berlin, Germany, 7.8Fr) and
long-term outcome data are awaited. In
addition, younger age at implantation is
associated with earlier lead failure [1].
In patients with diﬃcult transvenous
access or repaired complex congenital
heart disease, innovative solutions may
be required to facilitate transvenous lead
deployment. The hemi-Fontan, Fontan
and atrial switch anatomies provide par-
ticular challenges, but the placement of
shock coils in a collateral or azygous vein
[31] are alternative options.
Generator and system selection
Asingle pace/sense ventricular lead, gen-
erally integrated within the shock lead,
is mandatory for sensing and deﬁbrilla-
tion and these single chamber systems
are capable of bradycardia support and
antitachycardia pacing (ATP) (. Fig. 3).
Evidence for selection of dual over sin-
gle coil leads in the CHD population is
limited and may complicate lead extrac-
tion. An atrial lead adds the capability of
atrial bradycardia pacing, AV sequential
pacing and atrial ATP. In theory, there
shouldalsobeenhancedrhythmdiscrim-
ination but a study of 168 CHD patients
with single versus dual chamber ICD has
suggested that there is no signiﬁcant re-
duction in inappropriate shocks in the
CHD patient group [27].
Non-transvenous systems
Non-transvenous systems remain appro-
priate inasubgroupofpatients, particular
Fontan and atrial switch patients. In con-
trast to the subcutaneous ICD (S-ICD),
these ICDsystems remain capable ofpro-
vidingantibradycardiaorantitachycardia
pacing, andmay also be deployed in very
small patients. Generators are generally
placed in the abdomen, with a shock coil
placed in the left thorax (pericardial or
pleural space, anteriorly or posteriorly)
and placement of the ventricular lead
epicardially ([5], . Fig. 2c, d). Cardiac
strangulation from epicardial coils in a
growing child has not been reported as
yet.
Subcutaneous
There is increasing evidence for the use
of subcutaneous ICD (Emblem S-ICD,
Boston Scientiﬁc, Boston, MA), avoiding
the potential intravascular and lead com-
plicationsofother systems. Theyare rela-
tively bulky and do not allow for conven-
tional pacing or antitachycardia pacing
and therefore may generally be more ap-
propriate for channelopathies and other
arrhythmias not associated with struc-
tural CHD. Generator erosion rates in
smaller patients are high, with 3 out of 7
childreninonecase series requiringreop-
eration for threatened erosion or wound
dehiscence [12].
Early evidence of eﬃcacy and compli-
cation rates is emerging, with relatively
promising results [11, 12, 23, 33]. Initial
concerns regarding sensing issues, inap-
propriate shocks and failure of conver-
sion of malignant arrhythmias seem to
have been broadly overcomewith appro-
priate programming and placement but
S-ICD remains a technology in its early
phases with limited use in the structural
CHD population [23]. However, its im-
plementation in patient groups with no
venous access to the heart is attractive
if pacing is not required (. Fig. 4) and
there is evidence of reduced lead fail-
ure rates compared to non-transvenous
systems [32].
Other solutions
For some patients a hybrid approach
may oﬀer the best solution, combining
transvenous with non-transvenous or
S-ICD systems, particularly where atrial
pacing is required (. Fig. 5). A transa-
trial approach (standard ICD lead placed
directly into ventricle via atrial wall) has
also been reported [5].
A further alternative is the wear-
able cardioverter-deﬁbrillator (LifeVest®,
ZOLL,Pittsburgh, PA)andtheWEARIT-
II registry provided a limited degree of
evidence foreﬃcacy in theCHDGROUP.
Out of 2000 patients, 163 had CHD and
a high therapy eﬃcacy was reported
in all groups [26]. Such a system may
play a role in decision-making prior to
more permanent system implantation
or a ﬁnal decision to withhold ICD
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Fig. 28 a Posteroanterior andb lateral radiographs demonstrating transvenous pacing system in an
18 kg childwith longQT (LQT) syndrome. Generator has beenplacedabdominallywith lead tunnelled
to left subclavian vein (cross).Note redundant loop to accommodate growth (star).c Posteroanterior
andd lateral radiographsdemonstratingamorecomplexhybridsystemina15kgchildwithLQTtype3.
The ﬁrst ICD implantedwas non-transvenous,with intrapericardial coil (asterisk) and epicardial sense
andpacing leads (white arrows). Subsequent failure of the epicardial pacing leadswith R-wave un-
dersensing and rising deﬁbrillation threshold necessitated upgrade of the systemwith subcutanous
coil (scc) and transvenousatrial (a) andventricular (v)pace andsense leads (candd courtesyof Jasveer
Mangat, Great Ormond Street Hospital, London)
therapybut successful clinical implemen-
tation would be highly dependent on
compliance.
Conﬁguration
The increased frequency of non-trans-
venous system implantation, in the con-
text of abnormal cardiac orientations,
presents a unique challenge in selecting
the optimal ICD conﬁguration. Us-
ing MRI derived heart-torso models,
attempts have been made to model elec-
trophysiological responses to simulated
deﬁbrillation and these pipelines have
yielded promising early results [35].
Clinical implementation remains several
steps away but there is likely to be a role
for such technologies in the future.
Long-termmanagement
Follow-up
Remote monitoring and device auto-
maticity have greatly facilitated follow-
up, withmany centres aiming for approx-
imately6-monthly face-to-face follow-up
for patients once systems are established.
Guidelines for the level of dependency
that can be placed upon remote moni-
toring systems remain to be determined
but from a practical perspective the ma-
jority of patients with CHD will require
on-going general cardiology review, in
addition to device management.
Defibrillation threshold testing
There is a general consensus for deﬁb-
rillation threshold (DFT) testing at new
implantation and lead revision but the
approach to testing at generator change
and general surveillance is more var-
ied. A study by Stephenson et al. in
2005 showed that routine DFT testing in
asymptomatic patients is unlikely to lead
to clinical changes and testing should in-
stead be guided by clinical indications,
such as change in lead position and sens-
ing/pacing characteristics [37]. The latest
ESCguidelines suggest thatperiodicDFT
testing of non-transvenous ICD systems
should be considered in young children
(class IIa, level C recommendation) but
the speciﬁcs are deliberately vague [42].
Cardiac magnetic resonance
imaging
The role of MRI for surveillance and in-
vestigation of CHD management con-
tinues to increase and non-cardiac MRI
is frequently indicated in the maturing
adult CHD population. There is there-
fore a role for MRI conditional systems
and the majority of manufacturers now
provide MRI conditional solutions for
ICDs (Medtronic: SureScan®, St Jude:
MRIReady, Biotronik: ProMRI®, Boston
Scientiﬁc: ImageReady®). Selected MRI
conditionalgeneratorsmustbecombined
with MRI conditional leads to provide
the necessary static magnetic, gradient
Herzschrittmachertherapie + Elektrophysiologie 2 · 2016 99
Schwerpunkt
Fig. 38Diagramof transvenous implantable cardioverter-deﬁbrillator implanted following Senning repair (patient aged
18 years) for transposition of the great arteries (a).Posteroanterior (b) and lateral (c) radiograph projections.Note ventricular
coil (V Coil) placed in the posterior LV via the venous baﬄe.A atrial sense/pace lead, SVCsuperior vena cava, RA right atrium.
AoAorta, PApulmonary artery, LA left atrium, RV right ventricle and LV left ventricle
Fig. 49 Patientwith se-
vere scoliosis, pulmonary
atresia, ventricular sep-
tal defect andmajor aor-
topulmonary collateral
arteries. a Computed to-
mography andb Balanced
steady state free preces-
sion (b-SSFP)magnetic res-
onance image. c Antero-




with excellent shock vec-
tor (subcutaneous coil has
been placed to the right of
the sternum, RV right ven-
tricle, LV left ventricle, SP
spine, ST sternum)
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Fig. 58Diagramof subcutaneous implantable
cardioverter-deﬁbrillator and transvenous
atrial pacemaker in patientwith lateral tunnel
Fontan (a). Posteroanterior (b) and lateral (c)
radiographs demonstrating single chamber
pacemaker (white cross)with lead to systemic
venous portion of the right atrium and subcu-
taneous implantable cardioverter-deﬁbrillator
(white star). Figure adaptedwith permission
fromChubb et al [7]
Fig. 68 Cardiacmagnetic resonance imaging in a patientwith congenital aortic stenosis (status
post-Ross procedure) andmagnetic resonance-conditional implantable cardioverter-deﬁbrillator,
demonstrating typical results for balance steady state free precession (b-SSFP) cine imaging. Lead
position is indicated bywhite arrows and the ring artefact related to the generator is seen at the top
left of panels (c) and (d). a four chamber view,b short axis, c three chamber view,d right ventricular
outﬂow tract view.RV right ventricle, LV left ventricle,Ao aorta, LA left atrium, PApulmonary artery
magnetic and high frequency (RF) ﬁeld
safety. Manufacturers all provide indi-
vidual guidelines but generally imaging
should be delayed until a minimum of 6
weeks following implantation and height
restrictions may apply if imaging is to be
performed on-label. There are also dif-
ferences in MR conditionality: full body
scan conditionality enables cardiac MRI
but some systems have exclusion zones
precluding cardiac MRI particularly at
3 Tesla.
Despite the MRI-conditionality of the
devices, substantial imaging artefacts re-
lated to the generator and leads should
be anticipated (. Fig. 6). The extent of
these artefacts is unpredictable but gen-
erally relate at least in part to proximity
of the generator to the heart and spe-
ciﬁc MR sequences may be more robust
than others. Consideration to imaging
prior to implantation should continue to
be made, even if an MR-conditional sys-
tem is to be implanted and continuous
cardiac monitoring should be employed
throughout scanning as ICD therapies
are switched oﬀ in MRI scan modes.
ICD-related complications
Inappropriate shocks and ICD
programming
Vehmeijer et al. [39] looked at 518 pa-
tients with adult congenital heart disease
(ACHD) across 16 studies and inappro-
priate shocks were reported in 25% of
patients over approximately 3.8 years of
follow-up. In children the ﬁgures were
similar with Berul et al. reporting inap-
propriate shocks in 70 out of 290 chil-
dren (24 %), albeit in the context of a
slightly lower adult inappropriate shock
rate (14%, p <0.05) [3].
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A minority of these events can be
traced back to lead failure or oversensing
but up to 85% are related to supraven-
tricular tachycardia (SVT) (including si-
nus tachycardia) [39, 41]. The ICD pro-
gramming therefore plays a key role in
theminimizationof shocks. Anumberof
approaches canbeadoptedand the taskof
balancing over-treatment against delay-
ing therapy is a delicate one [22]. Device
technologies continue to evolve, but indi-
vidual tailoringofdevicesremainscrucial
to reduce inappropriate therapies. This
should be performed in the knowledge of
pre-existing arrhythmia characteristics,
but also noting that these very charac-
teristics may vary widely from episode
to episode.
Faster cut-oﬀ rates, especially in chil-
dren, will reduce the chance of SVTs
falling into the therapy zone. In some
cases where there is signiﬁcant overlap
between appropriate sinus tachycardia
and ventricular arrhythmia rates, there
is a role for beta-blockade, which may
also reduce the incidence of atrial ar-
rhythmias [4]. Relativelyslowintra-atrial
re-entrant arrhythmias predispose to 1:1
conduction, particularly in children, and
may necessitate the implementation of
manufacturer-speciﬁc discriminator al-
gorithms, such as morphology and onset
analysis; however, the use of dual cham-
ber, rather than single chamber, systems
has not been shown to provide added
protection from inappropriate shocks in
this patient group [27]. Catheter ablation
should be used when possible to reduce
inappropriate shocks.
ATP employs burst pacing algorithms
to interrupt re-entrant tachycardia in the
atrium or ventricle, either of which may
deteriorate to a rhythm precipitating loss
of cardiac output. Non-CHD trials have
demonstrated the safety, eﬃcacy and pa-
tient acceptability of these programming
options [30]. ATP should also be em-
ployed in the CHD population, where
they have been shown to be successful
in terminating a high proportion of VT
episodes [14].
Other complications
The rate for other complications in the
CHD population is higher than that seen
in large non-CHD cohorts, with compli-
cation rates around 25% over 3.5 years,
compared to 14% in the non-CHD pop-
ulation over a similar follow-up period
(Sudden Cardiac Death in Heart Failure
Trial, SCD-HeFT) [2, 39, 41].
The most common complication is
lead failure or dislodgement, which is
likely to represent a combination of
anatomical complexity compromising
lead positioning and the active lifestyle
of the predominantly young population.
In the large PLEASE study, Atallah et
al. clearly demonstrated the association
of lead failure with younger implanta-
tion age and Sprint Fidelis leads, with
an overall actual yearly failure rate of
2.3% for non-Fidelis leads [1]. Lead
and generator infections are much more
rare but present signiﬁcant management
problems and morbidity.
Lead extraction
In general, ICD lead extraction appears
to be feasible, reasonably safe but tech-
nically diﬃcult [1, 6, 29]. In the PLEASE
study, lead extraction was achieved for
143 leads, without mortality but with
a 4.3 % rate of major complications [1].
Half of all lead extractions required ad-
vanced tools, including locking stylets
and powered sheaths and technical skill
andoperatorexperienceare an important
codeterminant of procedural success.
Quality of life
ICD therapy undoubtedly has life-sav-
ing potential when deployed in the cor-
rect patient group; however, a signiﬁ-
cant number of patients have psycholog-
ical consequences, particularly amongst
those that have experienced shocks. In
large cohort studies of non-CHD pa-
tients, there was no overall diﬀerence
in quality of life for those randomized
to ICD therapy. However, in a prospec-
tive multicentre study from Alliance for
AdultResearch inCongenitalCardiology
it was noted that CHD ICD recipients ex-
perienced a high level of shock-related
anxiety, with associated impact on sex-
ual function in both sexes [8]. In par-
allel, studies of children with ICD have
also demonstrated a signiﬁcant impact
on quality of life [9]. The mitigation of
these adverse eﬀects on quality of life,
throughmeasures suchaspsychotherapy,
remains to be established.
Conclusion
The use of ICD therapy in CHD is a
life-saving treatment in appropriately se-
lected patients. The majority of systems
are implanted transvenously but novel
and innovative techniques may be re-
quired and in some cases a non-transve-
nous solution may be most appropriate.
Complication rates, including inappro-
priate shocks and lead failures are higher
than those seen in the non-CHDpopula-
tion and life-long exposure to these risks
should be carefully weighed up against
the beneﬁt the patient is anticipated to
derive from the system. Large and inclu-
sive registries, with good follow-up are
needed to provide robust data on pa-
tient management, including indications
for primary prevention ICD implanta-
tion. This, combined with evolving gen-
erator, lead and programming technolo-
gies, should continue to improve ICD
management for these complex patients.
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